Literature DB >> 34258904

Cardiac manifestations of COVID-19.

Agata Bielecka-Dabrowa1,2, Anna Cichocka-Radwan2, Joanna Lewek1,2, Filip Pawliczak1,2, Marek Maciejewski2, Maciej Banach1,2.   

Abstract

COVID-19 is a novel viral infection caused by severe acute respiratory syndrome (SARS) beta-coronavirus. Epidemiological status changes dynamically as the pandemy is far from ending. Several complications of presented virus may be similar to those observed in other viral infections. Despite lacking data, the heart involvement may be comparable to cardiac complications observed previously in those with SARS as well as Middle East Respiratory Syndrome (MERS). In COVID-19 we observe elevated levels of cardiac biomarkers, such as natriuretic peptides, troponins, myoglobin, C-reactive protein (CRP), interleukin-2 (IL-2), interleukin-6 (IL-6) and ferritin, which is likely the result of myocardial injury. The possible mechanisms of cardiovascular injury include direct toxicity through the viral invasion of cardiac myocytes, ACE-2 receptor-mediated CV (cardiac and endothelial) injury, microvascular dysfunction and thrombosis and cytokine release syndrome (mainly IL-6 mediated). Cardiac manifestations of COVID-19 are focal or global myocardial inflammation, necrosis, ventricular dysfunction, heart failure and arrhythmia.
© 2021 The Author(s). Published by IMR Press.

Entities:  

Keywords:  COVID-19; Cardiac manifestations; Coronavirus; Heart failure; SARS-CoV-2

Year:  2021        PMID: 34258904     DOI: 10.31083/j.rcm2202043

Source DB:  PubMed          Journal:  Rev Cardiovasc Med        ISSN: 1530-6550            Impact factor:   2.930


  4 in total

Review 1.  COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities.

Authors:  Theresa Maitz; Dominic Parfianowicz; Ashley Vojtek; Yasotha Rajeswaran; Apurva V Vyas; Rahul Gupta
Journal:  Curr Probl Cardiol       Date:  2022-03-26       Impact factor: 16.464

2.  Predictors of Long COVID in Patients without Comorbidities: Data from the Polish Long-COVID Cardiovascular (PoLoCOV-CVD) Study.

Authors:  Michał Chudzik; Joanna Lewek; Joanna Kapusta; Maciej Banach; Piotr Jankowski; Agata Bielecka-Dabrowa
Journal:  J Clin Med       Date:  2022-08-25       Impact factor: 4.964

Review 3.  COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports.

Authors:  Szymon Urban; Michał Fułek; Mikołaj Błaziak; Gracjan Iwanek; Maksym Jura; Katarzyna Fułek; Mateusz Guzik; Mateusz Garus; Piotr Gajewski; Łukasz Lewandowski; Jan Biegus; Piotr Ponikowski; Przemysław Trzeciak; Agnieszka Tycińska; Robert Zymliński
Journal:  J Clin Med       Date:  2022-09-21       Impact factor: 4.964

4.  SARS-CoV-2 Nsp6 damages Drosophila heart and mouse cardiomyocytes through MGA/MAX complex-mediated increased glycolysis.

Authors:  Jun-Yi Zhu; Guanglei Wang; Xiaohu Huang; Hangnoh Lee; Jin-Gu Lee; Penghua Yang; Joyce van de Leemput; Weiliang Huang; Maureen A Kane; Peixin Yang; Zhe Han
Journal:  Commun Biol       Date:  2022-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.